Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle:in vivostudy

Abstract

Exogenous administration of MI significantly improves semen's parameters both in patients with OA and in normal fertile men.

Inositol and In Vitro Fertilization with Embryo Transfer

“…Spermatozoa concentrations are higher in both Groups A and B. In conclusion, they showed that MYO supplementation significantly improves semen's parameters both in patients with OA and in normal fertile men [5]. …”

“…Studies demonstrate that the use of inositol in male patients affected by oligoasthenoteratozoospermia can improve sperm cell parameters and consequently the impact of fertilization rate and embryo quality leading to high percentage of pregnancy [5]. …”

Conservative Nonhormonal Options for the Treatment of Male Infertility: Antibiotics, Anti-Inflammatory Drugs, and Antioxidants

“…On this basis, the therapeutic use of MYO has been suggested in both in vivo and in vitro assisted reproductive techniques. Accordingly, oral supplementation with MYO seems to improve sperm parameters [146, 148, 149]. In particular, a double-blind, randomized, placebo-controlled study showed that patients with idiopathic infertility, treated for three months with MYO (2 g twice daily), had a significant increase of sperm concentration, total count, progressive motility, and acrosome-reacted spermatozoa.…”

Comment on “Inositols: from physiology to rational therapy in gynecological clinical practice”

“…Regarding metabolic profile, we recently suggested [3] that D-Chiro-Inositol (DCI) and MyoInositol (MI) metabolic derivatives work in synergy with each other: MI induces glucose transporter type 4 translocation to the cell membrane, thus enhancing cellular uptake of glucose; DCI stimulates pyruvate dehydrogenase, thus supporting adenosine triphosphate production through the Krebs' cycle; both MI and DCI stimulate glycogen synthase, thus supporting glucose conversion to glycogen stored inside cells; finally, MI derivatives inhibits adenylate cyclase enzyme, which controls free fatty acid release. Reflecting these elements on the clinical management, we recently showed MI beneficial effects on semen parameters before in vitro fertilization [4] and that both the isoforms of inositol and combined therapy were effective in improving ovarian function and metabolism in patients with PCOS, although MI showed the most marked effect on the metabolic profile, whereas DCI reduced hyperandrogenism better [2]. Although Unfer et al [1] proposed MI:DCI ratio of 40:1 as the most appropriate, we solicit further studies to establish the best therapeutic strategies based on patient's clinical condition, also in combination with other nutraceuticals [5].…”